Amgen Inc. is a biotechnology company that discovers, develops, manufactures, and delivers medicines for areas of high unmet medical need. Operating in a single segment focused on human therapeutics, the company markets products such as Repatha for cardiovascular risk, UPLIZNA for IgG4-related disease and myasthenia gravis, IMDELLTRA for small cell lung cancer, TEZSPIRE for chronic rhinosinusitis, and TEPEZZA for thyroid eye disease. Its pipeline includes MariTide for chronic weight management and Type 2 diabetes, and TAVNEOS for ANCA-associated vasculitis, which was developed by ChemoCentryx, a subsidiary acquired in 2022. Amgen serves markets in the United States, Europe, Japan, China, and other regions in Asia and Latin America. The company was incorporated in 1980.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage amgen.com
Sector Healthcare IR page amgen.com/responsibility/healthy-people/community-investment
Tags
biotechnology, human therapeutics, cardiovascular disease, oncology, immunology, endocrinology, metabolic disorders, antibody-peptide conjugates, glp-1 receptor agonists, small cell lung cancer, thyroid eye disease, myasthenia gravis, Repatha, UPLIZNA, IMDELLTRA, IMDYLLTRA, TEZSPIRE, TEPEZZA, MariTide, TAVNEOS, ChemoCentryx, Bemarituzumab, Rocatinlimab
Press page amgen.com/newsroom/press-releases

Metrics

Valuation  
Market cap $ 227.995B
Market cap (USD) $ 227.995B
P/E 24.45
PEG 4.38
P/BV 15.89
P/S 5.86
P/OCF 18.94
P/FCF 23.80
Dividend yield 2.3%
Turnover / mcap —
Returns  
ROE 106.1%
ROI 12.2%
ROIC 12.3%
Profit margin 21.0%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 5.6%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 376.3%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 92
Quality score 36.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 36.751B 33.424B 28.19B 26.323B 25.979B 25.424B 23.362B 23.747B 22.849B 22.991B 21.662B 20.063B 18.676B 17.265B 15.582B 15.053B 14.642B 15.003B 14.771B 14.268B 12.43B 10.55B 8.356B 5.523B 4.016B 3.629B
Net profit 7.711B 4.09B 6.717B 6.552B 5.893B 7.264B 7.842B 8.394B 1.979B 7.722B 6.939B 5.158B 5.081B 4.345B 3.683B 4.627B 4.605B 4.196B 3.166B 2.95B 3.674B 2.363B 2.26B -1.392B 1.12B 1.139B
Free cash flow 8.1B 10.394B 7.359B 8.785B 8.381B 9.889B 8.532B 10.558B 10.513B 9.616B 8.483B 7.837B 5.598B 5.193B 4.552B 5.207B 5.806B 5.316B 4.134B 4.171B 4.044B 2.361B 2.21B 1.59B 1.038B 1.197B

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 327.31 260.64 288.02 262.64 224.97 229.92 241.07 194.67 173.9 146.21 162.33 159.29 114.08 86.2 64.21 54.9 56.57 57.74 61.24 70.15 — — — — — —
Price performance 12m 0.26 -0.1 0.1 0.17 -0.02 -0.05 0.24 0.12 0.19 -0.1 0.02 0.4 0.32 0.34 0.17 -0.03 -0.02 -0.06 -0.13 — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 3.17B 3.24B 3.58B 4.06B 4.53B 4.9B 5.56B 7.27B 6.78B 9.57B
↳ YoY growth +5.7% +2.3% +10.6% +13.3% +11.5% +8.2% +13.6% +30.6% -6.7% +41.1%
↳ 5y CAGR +1.8% +5.2% +5.8% +9.8% +8.6% +9.1% +11.4% +15.2% +10.8% +16.2%
Borrowings, current (USD) 4.4B 1.15B 4.42B 2.95B 91M 87M 1.59B 1.44B 3.55B 4.6B
Borrowings, non-current (USD) 30.2B 34.2B 29.5B 27B 32.9B 33.2B 37.4B 63.2B 56.5B 50B
Lease liabilities (USD) — — — 528M 459M 670M 695M 810M 780M 831M
Cash and deposits (USD) 3.24B 3.8B 6.95B 6.04B 6.27B 7.99B 7.63B 10.9B 12B 9.13B
Intangible assets (USD) 10.3B 8.61B 7.44B 19.4B 16.6B 15.2B 16.1B 32.6B 27.7B 22.3B
Right-of-use assets (USD) — — — 469M 408M 566M 579M 651M 557M 602M
Net debt (borrowings + leases - cash) (USD) 31.4B 31.5B 27B 24.4B 27.2B 26B 32B 54.5B 48.9B 46.3B
Cash flow detail
Operating cash flow (USD) 10.4B 11.2B 11.3B 9.15B 10.5B 9.26B 9.72B 8.47B 11.5B 9.96B
Purchases of property, plant and equipment (USD) -738M -664M -738M -618M -608M -880M -936M -1.11B -1.1B -1.86B
Purchases of intangible assets (USD) -99M — — — — — — — — —
Change in receivables (cash effect) (USD) -214M -58M -378M -504M -427M -429M -746M -1.02B 441M -2.68B
Change in inventories (cash effect) (USD) -80M 133M -3M -66M -215M -165M -742M 491M 2.53B 886M
Change in payables (cash effect) (USD) -44M 424M -143M 164M 45M -69M 154M -402M 312M 428M
Dividends paid (cash effect) (USD) -3B -3.37B -3.51B -3.51B -3.76B -4.01B -4.2B -4.56B -4.83B -5.12B
Share buybacks (cash effect) (USD) -2.97B -3.16B -17.8B -7.7B -3.49B -4.98B -6.36B 0.00 -200M 0.00
Interest paid (cash effect) (USD) -1.2B -1.3B -1.5B -1.3B -1.2B -1.2B -1.2B -2.4B -3.3B -2.9B
Income taxes paid (cash effect) (USD) -1.1B -1.5B -1.9B -1.9B -1.4B -1.9B -2.4B -3.4B -2.9B -4.3B
Share-based compensation (USD) 311M 329M 311M 308M 330M 341M 401M 431M 530M 494M
Operating cash flow before change in receivables (USD) 10.6B 11.2B 11.7B 9.65B 10.9B 9.69B 10.5B 9.49B 11B 12.6B
Free cash flow (OCF - PPE - intangibles) (USD) 9.52B 10.5B 10.6B 8.53B 9.89B 8.38B 8.79B 7.36B 10.4B 8.1B
Income detail
Research and development expense (USD) 3.84B 3.56B 3.74B 4.12B 4.21B 4.82B 4.43B 4.78B 5.96B 7.27B
↳ 5y CAGR +3.9% +1.1% -1.8% -0.9% +0.7% +4.6% +4.5% +5.1% +7.7% +11.6%
Total comprehensive income (USD) 7.73B 1.77B 8.31B 8.08B 6.81B 6.08B 7.12B 6.66B 4.31B 7.52B
Comprehensive income to owners (USD) 7.73B 1.77B 8.31B 8.08B 6.81B 6.08B 7.12B 6.66B 4.31B 7.52B
Reported Feb 14, 2017 Feb 13, 2018 Feb 13, 2019 Feb 12, 2020 Feb 9, 2021 Feb 16, 2022 Feb 9, 2023 Feb 14, 2024 Feb 14, 2025 Feb 13, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Findings Represent Largest and Most Rigorous Head-to-Head Real-World Outcomes Analysis of Repatha and Ezetimibe

Study Examined More Than Half a Million Adults Living with Heart Disease

Results Provide Important New Clinical Evidence to Inform Non-Statin Treatment Decisions for Patients

THOUSAND OAKS, Calif., Nov. 5, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced results from a large real-world study showing that treatment with Repatha® (evolocumab) reduced the risk of fatal or nonfatal heart attacks by 20% compared with ezetimibe in people with atherosclerotic cardiovascular disease (ASCVD) and prior statin use. The study followed more than 544,000 adults for up to four years. The findings were published in The American Journal of Preventive Cardiology.

"We have known for decades that lowering LDL cholesterol reduces cardiovascular risk, yet many patients with ASCVD cannot reach recommended levels with statins alone," said Paul Burton, M.D., Ph.D., chief medical officer at Amgen. "For physicians deciding what treatment to add next, whether that's prescribing patients Repatha or ezetimibe, this large real-world study provides clear evidence to help inform that choice. Patients who received Repatha had a 20% lower risk of heart attack or death from a heart attack compared with those who received ezetimibe."

Among patients with a baseline low-density lipoprotein cholesterol (LDL-C) measurement (N = 225,048), the four-year cumulative risk of heart attack was lower with Repatha than with ezetimibe, an oral medicine that lowers LDL-C by limiting cholesterol absorption (5.88% vs. 7.76%). The analysis compared cardiovascular outcomes across a large patient population using rigorous analytical methods. The study is distinctive in its scale and approach to analyzing outcomes in the real world, requiring precise investigative methods to provide a large, practical evidence base that evaluates cardiovascular outcomes between the two treatments. Its findings provide a practical real-world complement to clinical trial evidence and may help inform clinical practice.

"While the recent ACC/AHA Multisociety Guideline update recognizes both ezetimibe and PCSK9 inhibitors like evolocumab as non-statin options for patients with ASCVD, clinicians have lacked direct cardiovascular outcomes evidence to help inform treatment choices for their patients that may allow them to fully achieve the recommended LDL-C goals of <70 mg/dL and <55 mg/dL," said Nihar Desai, M.D., M.P.H., associate professor of medicine and vice chief of the Section of Cardiovascular Medicine, Yale University School of Medicine. "These findings provide important comparative data that can help clinicians distinguish between these treatment options and make more informed choices to reduce their patients' cardiovascular risk."

This real-world study used a rigorous design that mirrors a randomized clinical trial to compare cardiovascular outcomes among adults with ASCVD who initiated Repatha or ezetimibe in routine U.S. clinical practice. The analysis leveraged de-identified data from the Komodo Healthcare Map® and applied a robust analytical approach to ensure that the two treatment groups were as similar as possible with respect to their baseline patient characteristics.

About the Real-World Comparative StudyThe Real-World Comparative Effectiveness of Evolocumab Versus Ezetimibe in Adults with Atherosclerotic Cardiovascular Disease: An Active-Comparator New-User Study is a non-interventional, active-comparator, new-user cohort study that applied a target trial framework to compare cardiovascular outcomes among adults with ASCVD and prior statin use who initiated evolocumab or ezetimibe in routine U.S. clinical care. The study included 544,103 adults identified in the Komodo Healthcare Map® database, including 64,421 who initiated evolocumab and 479,682 who initiated ezetimibe between 2017 and 2024, with follow-up through June 2026. The primary outcome was fatal or nonfatal myocardial infarction (MI) over up to four years of follow-up.

Treatment with evolocumab lowered the rate of fatal or nonfatal MI by 20% compared with ezetimibe (HR, 0.80; 95% CI, 0.70-0.91). Among patients without an available baseline LDL-C measurement, the corresponding four-year cumulative risks were 5.65% and 7.06%, respectively. The study used inverse probability weighting to balance measured baseline characteristics between treatment groups and a calibrated estimator to account for incomplete availability of baseline LDL-C; a prespecified sensitivity analysis that continued follow-up regardless of changes in background statin therapy produced consistent results.

Amgen's Commitment toCardiovascularInnovationCardiovascular disease (CVD) remains a major global health threat, linked to multiple interrelated risk factors like high LDL-C, Lp(a), obesity, diabetes and hypertension.1,2 These risks often coexist and require a comprehensive approach to prevention and care. Amgen is taking bold action, building on decades of leadership in CVD through LDL-C management to advance additional innovative, investigational treatments in the pipeline targeting common drivers of CVD. By combining scientific innovation with strategic partnerships to drive earlier testing, better care and broader access, Amgen's efforts reflect a sustained commitment to advancing both the science and the system of CV care.

Amgen's Center for Observational ResearchAmgen's Center for Observational Research (CfOR) is a global, multidisciplinary organization dedicated to bringing epidemiologic and data science expertise together with real-world data (RWD) to generate evidence that advances Amgen's mission to serve patients. Across the medicine lifecycle, CfOR helps deepen understanding of disease and how care is delivered in clinical practice, evaluate the comparative effectiveness and safety of Amgen's medicines, and accelerate the development of innovative therapies. By paving the way for groundbreaking applications of RWD and real-world evidence (RWE), CfOR is helping progress the science that informs healthcare decision-making and deliver meaningful benefit for patients and the broader healthcare community.

About RepathaRepatha is a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). Repatha binds to PCSK9 and inhibits circulating PCSK9 from binding to the low-density lipoprotein (LDL) receptor (LDLR), preventing PCSK9-mediated LDLR degradation and permitting LDLR to recycle back to the liver cell surface. By inhibiting the binding of PCSK9 to LDLR, Repatha increases the number of LDLRs available to clear LDL from the blood, thereby lowering LDL-C levels.

Repatha is one of the most extensively studied PCSK9 inhibitors, with clinical and real-world evidence across diverse populations and CV risk profiles.2 The clinical benefits and safety of Repatha have been studied for 15 years in 51 clinical trials with over 57,000 patients.3 Repatha is the only PCSK9 inhibitor to demonstrate a significant reduction of cardiovascular events as both high-risk primary and secondary prevention, with patients achieving and maintaining dramatic LDL-C reductions using Repatha once every two weeks.4,5

Repatha was first approved in 2015 and has since been used by approximately 9 million patients globally.6 In August 2025, the U.S. Food and Drug Administration broadened the approved use of Repatha to include adults at increased risk for major adverse CV events due to uncontrolled LDL-C. In August 2026, the European Commission approved an expanded indication for the use of Repatha in adults with established or high risk for ASCVD to reduce CV risk by lowering LDL-C levels, as an adjunct to correction of other risk factors, based on results from the Phase 3 VESALIUS-CV trial. Repatha is approved in 75 countries, including the U.S., Japan, Canada and in all 28 countries that are members of the European Union.7 Applications in other countries are pending. Repatha is the most covered PCSK9 inhibitor monoclonal antibody in the U.S.8 ~96% of patients are covered for Repatha across insurance types, with most patients paying less than $50/month.9 Through AmgenNow™, a direct-to-patient program, Repatha is available to patients at nearly 60% below the monthly list price.

INDICATIONS

Repatha® is indicated:

  • To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, coronary revascularization, or any ischemia-driven arterial revascularization) in adults at increased risk for these events.

  • As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in:

  • adults with hypercholesterolemia.

  • adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).

  • adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH).

The safety and effectiveness of Repatha® have not been established in pediatric patients with HeFH or HoFH who are younger than 10 years old or in pediatric patients with other types of hypercholesterolemia.

IMPORTANT SAFETY INFORMATION

  • Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®. Serious hypersensitivity reactions including angioedema have occurred in patients treated with Repatha®.

  • Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, have been reported in patients treated with Repatha®. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with Repatha®, treat according to the standard of care, and monitor until signs and symptoms resolve.

  • Adverse Reactions in Adults with Hypercholesterolemia: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.

From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. Hypersensitivity reactions occurred in 5.1% and 4.7% of Repatha®-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for Repatha® and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

  • Adverse Reactions in the FOURIER Cardiovascular Outcomes Trial: The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: diabetes mellitus (8.8% Repatha®, 8.2% placebo), nasopharyngitis (7.8% Repatha®, 7.4% placebo), and upper respiratory tract infection (5.1% Repatha®, 4.8% placebo).

Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with Repatha® compared with 7.7% in patients that received placebo.

  • **Adverse Reactions in the VESALIUS Cardiovascular Outcomes Trial:**The safety profile of Repatha® in this trial was consistent with the known safety profile of Repatha®.

  • **Adverse Reactions in Pediatric Patients with HeFH:**The most common adverse reactions (>5% of patients treated with Repatha® and more frequently than placebo) were: nasopharyngitis, headache, oropharyngeal pain, influenza, and upper respiratory tract infection.

  • Adverse Reactions in Adults and Pediatric Patients with HoFH: In a 12-week study in 49 patients, the adverse reactions that occurred in at least two patients treated with Repatha® and more frequently than placebo were: upper respiratory tract infection, influenza, gastroenteritis, and nasopharyngitis. In an open-label extension study in 106 patients, including 14 pediatric patients, no new adverse reactions were observed.

  • Immunogenicity: Repatha® is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity with Repatha®.

Pleaseseefull Prescribing Information.

About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines.

More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, heart disease, inflammatory conditions, rare diseases and obesity and obesity-related conditions.

Amgen has been consistently recognized for innovation and workplace culture, including honors from Fast Company and Forbes. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.

One Amgen Center Drive Bull 4 Bear 0 Results

Thousand Oaks, CA 91320-1799

Telephone 805-447-1000

www.amgen.com

AMGEN REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS

THOUSAND OAKS, Calif. (Nov. 3, 2026) - Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2026.

“Amgen delivered another strong quarter as our strategy for long-term growth continued to produce results across the enterprise,” said Robert A. Bradway, chairman and chief executive officer. “The strength of our commercial portfolio, combined with important clinical advances and a promising late-stage pipeline, reinforces our confidence in Amgen’s ability to deliver durable growth well into the next decade.”

Key results include:

•For the third quarter, total revenues increased 8% to $10.4 billion in comparison to the third quarter of 2025.

◦Product sales grew 8%, driven by volume growth.

◦Seventeen products delivered at least double-digit sales growth in the third quarter.

◦Seventeen products are annualizing at more than $1 billion based on third quarter sales.

•GAAP earnings per share (EPS) increased 19% from $5.93 to $7.08 for the third quarter, driven by higher revenues.

THOUSAND OAKS, Calif., Nov. 3, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the third quarter of 2026.

"Amgen delivered another strong quarter as our strategy for long-term growth continued to produce results across the enterprise," said Robert A. Bradway, chairman and chief executive officer. "The strength of our commercial portfolio, combined with important clinical advances and a promising late-stage pipeline, reinforces our confidence in Amgen's ability to deliver durable growth well into the next decade."

Key results include:

  • For the third quarter, total revenues increased 8% to $10.4 billion in comparison to the third quarter of 2025.

  • Product sales grew 8%, driven by volume growth.

  • Seventeen products delivered at least double-digit sales growth in the third quarter.

  • Seventeen products are annualizing at more than $1 billion based on third quarter sales.

  • GAAP earnings per share (EPS) increased 19% from $5.93 to $7.08 for the third quarter, driven by higher revenues.

  • For the third quarter, GAAP operating income increased from $2.5 billion to $3.7 billion, and GAAP operating margin increased 9.9 percentage points to 37.5%.

  • Non-GAAP EPS increased 14% from $5.64 to $6.45 for the third quarter, primarily driven by higher revenues, partially offset by higher operating expenses.

  • For the third quarter, non-GAAP operating income increased from $4.3 billion to $4.7 billion, and non-GAAP operating margin increased 0.2 percentage points to 47.3%.

  • The Company generated $3.7 billion of free cash flow in the third quarter of 2026 versus $4.2 billion in the third quarter of 2025, driven by changes in working capital, with the third quarter of 2025 benefiting from the timing of rebates and collections, partially offset by current period business performance.

References in this release to "non-GAAP" measures, measures presented "on a non-GAAP basis," and "free cash flow" (computed by subtracting capital expenditures from operating cash flow) refer to non-GAAP financial measures. Adjustments to the most directly comparable GAAP financial measures and other items are presented on the attached reconciliations. Refer to Non-GAAP Financial Measures below for further discussion.

Product Sales Performance

General Medicine

  • Repatha® (evolocumab) sales increased 37% year-over-year to $1,085 million in the third quarter, primarily driven by volume growth.

  • **EVENITY® (romosozumab-aqqg)**sales increased 39% year-over-year to $751 million in the third quarter, driven by volume growth.

  • Prolia® (denosumab) sales decreased 45% year-over-year to $632 million in the third quarter as multiple biosimilars have launched globally. The decrease was driven by 23% lower volume with the remainder driven equally by lower net selling price and changes to estimated sales deductions.

Rare Disease

  • TEPEZZA® (teprotumumab-trbw) sales decreased 6% year-over-year to $526 million in the third quarter, driven by lower inventory levels.

  • KRYSTEXXA® (pegloticase) sales increased 31% year-over-year to $419 million in the third quarter, primarily driven by higher net selling price.

  • UPLIZNA® (inebilizumab-cdon) sales increased 191% year-over-year to $451 million in the third quarter, primarily driven by volume growth.

  • TAVNEOS® (avacopan) sales decreased 2% year-over-year to $105 million in the third quarter, driven by 9% lower volume, 8% unfavorable changes to estimated sales deductions and 5% lower net selling price, partially offset by higher inventory levels. We continue to engage with the U.S. Food and Drug Administration (FDA) and believe that TAVNEOS demonstrates clinical effectiveness and a favorable benefit-risk profile.

Inflammation

  • TEZSPIRE® (tezepelumab-ekko) sales increased 43% year-over-year to $538 million in the third quarter, driven by volume growth.

  • **Otezla® (apremilast)**sales decreased 18% year-over-year to $481 million in the third quarter, driven by 13% lower volume, 9% unfavorable changes to estimated sales deductions and 4% lower net selling price, partially offset by higher inventory levels.

  • Enbrel® (etanercept) sales increased 5% year-over-year to $611 million in the third quarter, driven by 15% favorable changes to estimated sales deductions and 8% higher inventory levels, partially offset by 14% lower net selling price, reflecting the ongoing impact of U.S. Medicare Part D price setting effective in 2026 under the Inflation Reduction Act, and lower volume.

  • **AMJEVITA® (adalimumab-atto)/AMGEVITA™ (adalimumab)**sales increased 24% year-over-year to $191 million in the third quarter, primarily driven by 18% volume growth and higher net selling price.

  • PAVBLU**®****(aflibercept-ayyh)** sales increased 41% year-over-year to $300 million in the third quarter, driven by 71% volume growth, partially offset by 18% lower net selling price.

Oncology

  • BLINCYTO® (blinatumomab) sales increased 27% year-over-year to $496 million in the third quarter, primarily driven by volume growth.

  • IMDELLTRA® (tarlatamab-dlle)/IMDYLLTRA™ (tarlatamab) sales increased 128% year-over-year to $406 million in the third quarter, driven by volume growth.

  • Vectibix® (panitumumab) sales increased 18% year-over-year to $335 million in the third quarter, primarily driven by volume growth.

  • KYPROLIS® (carfilzomib) sales decreased 8% year-over-year to $330 million in the third quarter, primarily driven by lower volume.

  • **LUMAKRAS®/LUMYKRAS™ (sotorasib)**sales increased 6% year-over-year to $102 million in the third quarter, driven by 14% volume growth, partially offset by 5% unfavorable changes to estimated sales deductions and lower inventory levels.

  • Nplate® (romiplostim) sales increased 3% year-over-year to $472 million in the third quarter. U.S. government orders were $65 million in Q3'26 compared to $90 million in Q3'25. Excluding these U.S. government orders, Nplate sales increased 11% year-over-year, primarily driven by volume growth.

  • **XGEVA® (denosumab)**sales decreased 47% year-over-year to $288 million in the third quarter as multiple biosimilars have launched globally. The decrease was primarily driven by 32% lower volume and 11% lower net selling price.

  • **MVASI® (bevacizumab-awwb)**sales decreased 21% year-over-year to $168 million in the third quarter, primarily driven by 11% lower net selling price and lower volume.

Established Products

  • Our established products, which consist of Aranesp® (darbepoetin alfa),Neulasta® (pegfilgrastim), andParsabiv® (etelcalcetide), generated $606 million of sales in the third quarter. Sales increased 14% year-over-year, driven by 19% higher net selling price, partially offset by 3% lower volume.

Product Sales Detail by Product and Geographic Region

| $Millions, except percentages | | Q3 '26 | | Q3 '25 | | YOY Δ |

| | | U.S | | ROW | | TOTAL | | TOTAL | | TOTAL |

| Repatha® | | $ 666 | | $ 419 | | $ 1,085 | | $ 794 | | 37 % |

| EVENITY® | | 557 | | 194 | | 751 | | 541 | | 39 % |

| Prolia® | | 409 | | 223 | | 632 | | 1,139 | | (45 %) |

| TEPEZZA® | | 441 | | 85 | | 526 | | 560 | | (6 %) |

| KRYSTEXXA® | | 419 | | — | | 419 | | 320 | | 31 % |

| UPLIZNA® | | 352 | | 99 | | 451 | | 155 | | * |

| TAVNEOS® | | 105 | | — | | 105 | | 107 | | (2 %) |

| Ultra-Rare products(1) | | 107 | | 3 | | 110 | | 200 | | (45 %) |

| TEZSPIRE® | | 538 | | — | | 538 | | 377 | | 43 % |

| Otezla® | | 428 | | 53 | | 481 | | 585 | | (18 %) |

| Enbrel® | | 605 | | 6 | | 611 | | 580 | | 5 % |

| AMJEVITA®/AMGEVITA™ | | 64 | | 127 | | 191 | | 154 | | 24 % |

| PAVBLU® | | 294 | | 6 | | 300 | | 213 | | 41 % |

| WEZLANA®/WEZENLA™ | | 8 | | 52 | | 60 | | 44 | | 36 % |

| BLINCYTO® | | 269 | | 227 | | 496 | | 392 | | 27 % |

| IMDELLTRA®/IMDYLLTRA™ | | 224 | | 182 | | 406 | | 178 | | * |

| Vectibix® | | 182 | | 153 | | 335 | | 284 | | 18 % |

| KYPROLIS® | | 209 | | 121 | | 330 | | 359 | | (8 %) |

| LUMAKRAS®/LUMYKRAS™ | | 55 | | 47 | | 102 | | 96 | | 6 % |

| Nplate® | | 347 | | 125 | | 472 | | 457 | | 3 % |

| XGEVA® | | 170 | | 118 | | 288 | | 539 | | (47 %) |

| MVASI® | | 128 | | 40 | | 168 | | 213 | | (21 %) |

| Aranesp® | | 95 | | 234 | | 329 | | 357 | | (8 %) |

| Neulasta® | | 178 | | 17 | | 195 | | 92 | | * |

| Parsabiv® | | 38 | | 44 | | 82 | | 84 | | (2 %) |

| Other products(2) | | 371 | | 49 | | 420 | | 317 | | 32 % |

| Total product sales | | $ 7,259 | | $ 2,624 | | $ 9,883 | | $ 9,137 | | 8 % |

| | | | | | | | | | | |

| * Change in excess of 100% | | | | | | | | | | |

| (1) Ultra-Rare products consist of PROCYSBI®, RAVICTI®, ACTIMMUNE®, QUINSAIR®, and BUPHENYL® |

| (2) Other products consist of KANJINTI®, AVSOLA®, Aimovig®, BKEMV®/BEKEMV™, RIABNI®, EPOGEN®, IMLYGIC®, NEUPOGEN®, DUEXIS®, RAYOS®, PENNSAID®, Sensipar®/Mimpara™, and Corlanor®. The Biosimilar products within Other products total $258 million in Q3 '26 and $151 million in Q3 '25. The Rare Disease products within Other products total $0 million in Q3 '26 and ($10) million in Q3 '25 |

Operating Expense, Operating Margin and Tax Rate Analysis

On a GAAP basis:

  • Total Operating Expenses decreased 5% year-over-year for the third quarter. Cost of Sales as a percentage of product sales decreased 5.5 percentage points, driven by lower amortization expense from acquisition-related assets and lower manufacturing costs, partially offset by higher profit share expense and changes in our sales mix. **Research & Development (R&D)**expenses increased 11% driven by higher spend in Research and Early Pipeline, including business development activity. Selling, General & Administrative (SG&A) expenses decreased 2% driven by lower general and administrative expenses, partially offset by higher commercial product-related expenses. Other operating expenses for the third quarter of 2026 totaled $76 million.

  • Operating Margin as a percentage of product sales increased 9.9 percentage points to 37.5%.

  • Tax Rate decreased 0.5 percentage points for the third quarter primarily driven by the change in earnings mix, including lower net unrealized gains on our equity investments, partially offset by net favorable items in the prior year as compared to the current year.

On a non-GAAP basis:

  • Total Operating Expensesincreased 8% year-over-year for the third quarter. Cost of Sales as a percentage of product sales increased 1.1 percentage points driven by higher profit share expense and changes in our sales mix, partially offset by lower manufacturing costs. R&Dexpenses increased 11% driven by higher spend in Research and Early Pipeline, including business development. SG&A expenses decreased 1% driven by lower general and administrative expenses, partially offset by higher commercial product-related expenses.

  • Operating Margin as a percentage of product sales increased 0.2 percentage points for the third quarter to 47.3%.

  • Tax Rate decreased 2.3 percentage points for the third quarter primarily driven by the change in earnings mix.

| $Millions, except percentages | | GAAP | | Non-GAAP |

| | | Q3 '26 | | Q3 '25 | | YOY Δ | | Q3 '26 | | Q3 '25 | | YOY Δ |

| Cost of Sales | | $ 2,788 | | $ 3,082 | | (10 %) | | $ 1,907 | | $ 1,662 | | 15 % |

| % of product sales | | 28.2 % | | 33.7 % | | (5.5) pts | | 19.3 % | | 18.2 % | | 1.1 pts |

| Research & Development | | $ 2,111 | | $ 1,900 | | 11 % | | $ 2,105 | | $ 1,890 | | 11 % |

| % of product sales | | 21.4 % | | 20.8 % | | 0.6 pts | | 21.3 % | | 20.7 % | | 0.6 pts |

| Selling, General & Administrative | | $ 1,680 | | $ 1,720 | | (2 %) | | $ 1,677 | | $ 1,700 | | (1 %) |

| % of product sales | | 17.0 % | | 18.8 % | | (1.8) pts | | 17.0 % | | 18.6 % | | (1.6) pts |

| Other | | $ 76 | | $ 329 | | (77 %) | | $ — | | $ — | | N/A |

| Total Operating Expenses | | $ 6,655 | | $ 7,031 | | (5 %) | | $ 5,689 | | $ 5,252 | | 8 % |

| | | | | | | | | | | | | |

| Operating Margin | | | | | | | | | | | | |

| Operating income as % of product sales | | 37.5 % | | 27.6 % | | 9.9 pts | | 47.3 % | | 47.1 % | | 0.2 pts |

| | | | | | | | | | | | | |

| Tax Rate | | 17.5 % | | 18.0 % | | (0.5) pts | | 15.9 % | | 18.2 % | | (2.3) pts |

| | | | | | | | | | | | | |

| pts: percentage points | | | | | | | | | | | | |

| N/A = not applicable | | | | | | | | | | | | |

Cash Flow and Balance Sheet

  • The Company generated $3.7 billion of free cash flow in the third quarter of 2026 versus $4.2 billion in the third quarter of 2025, driven by changes in working capital, with the third quarter of 2025 benefiting from the timing of rebates and collections, partially offset by current period business performance.

  • The Company declared a third quarter 2026 dividend on July 30, 2026 of $2.52 per share that was paid on September 11, 2026 to all stockholders of record as of August 21, 2026, representing a 6% increase from the same period in 2025.

  • During the third quarter of 2026, there were no repurchases of shares of common stock under our stock repurchase program.

  • Cash and cash equivalents totaled $13.2 billion and debt outstanding totaled $54.0 billion as of September 30, 2026.

| $Billions, except shares | | Q3 '26 | | Q3 '25 | | YOY Δ |

| Operating Cash Flow | | $ 4.2 | | $ 4.7 | | $ (0.4) |

| Capital Expenditures | | $ 0.6 | | $ 0.4 | | $ 0.2 |

| Free Cash Flow | | $ 3.7 | | $ 4.2 | | $ (0.6) |

| Dividends Paid | | $ 1.4 | | $ 1.3 | | $ 0.1 |

| Share Repurchases | | $ 0.0 | | $ 0.0 | | $ 0.0 |

| Average Diluted Shares (millions) | | 546 | | 542 | | 4 |

| | | | | | | |

| Note: Numbers may not add due to rounding | | | | |

| $Billions | | 9/30/26 | | 12/31/25 | | YTD Δ |

| Cash and Cash Equivalents | | $ 13.2 | | $ 9.1 | | $ 4.1 |

| Debt Outstanding | | $ 54.0 | | $ 54.6 | | $ (0.6) |

| | | | | | | |

| Note: Numbers may not add due to rounding | | | | |

2026****Guidance

For the full year 2026, the Company expects:

  • Total revenues in the range of $38.9 billion to $39.7 billion.

  • On a GAAP basis, EPS in the range of $18.34 to $19.28, and a tax rate in the range of 14.5% to 16.0%.

  • On a non-GAAP basis, EPS in the range of $22.90 to $23.70, and a tax rate in the range of 15.0% to 16.5%.

  • Capital expenditures to be approximately $2.6 billion.

  • Share repurchases not to exceed $3.0 billion.

Third****Quarter Product and Pipeline Update

The Company provided the following updates on selected product and pipeline programs:

General Medicine

MariTide™****(maridebart cafraglutide/AMG 133)

  • MariTide is a differentiated antibody-peptide conjugate that activates the glucagon-like peptide-1 (GLP-1) receptor and antagonizes the glucose-dependent insulinotropic polypeptide receptor (GIPR). MariTide's long-acting design supports starting with monthly dosing, and staying on MariTide with as few as four or six doses per year.

  • MARITIME-1, a Phase 3 study of MariTide for chronic weight management, is ongoing in adults living with obesity or overweight, without Type 2 diabetes (T2D).

  • MARITIME-2, a Phase 3 study of MariTide for chronic weight management, is ongoing in adults living with obesity or overweight, with T2D.

  • MARITIME-CV, a Phase 3 study of MariTide on cardiovascular (CV) outcomes, has completed enrollment of adults living with established atherosclerotic cardiovascular disease and obesity or overweight.

  • MARITIME-HF, a Phase 3 study of MariTide on reduction of heart failure (HF) events and cardiovascular risk, is enrolling adults living with heart failure with preserved or mildly reduced ejection fraction and obesity.

  • MARITIME-OSA-1, a Phase 3 study of MariTide, has completed enrollment of adults living with obstructive sleep apnea (OSA) on positive airway pressure therapy and living with obesity or overweight.

  • MARITIME-OSA-2, a Phase 3 study of MariTide, has completed enrollment of adults living with OSA not on positive airway pressure therapy and living with obesity or overweight.

  • MARITIME-SWITCH, a Phase 3 study of MariTide, is enrolling adults living with obesity or overweight who will be switching from weekly tirzepatide or weekly semaglutide to MariTide on an every eight-week or quarterly dosing schedule.

  • MARITIME-1 EXTENSION, a Phase 3 long-term extension study of MariTide, to evaluate the maintenance of weight loss with monthly, every eight-week or quarterly dosing, is enrolling adults living with obesity or overweight without T2D who completed the MARITIME-1 study.

  • MARITIME-2 EXTENSION, a Phase 3 long-term extension study of MariTide, to evaluate the maintenance of weight loss with monthly and every eight-week dosing, is enrolling adults living with obesity or overweight with T2D who completed the MARITIME-2 study.

  • MARITIME-T2D-3 study, a Phase 3 study of MariTide, to evaluate efficacy compared to semaglutide, was initiated and is enrolling adults living with T2D.

  • Two additional Phase 3 studies of MariTide in people living with T2D will be initiated in Q4 2026.

  • A Phase 2b study of MariTide to assess the effect of MariTide on liver fat reduction and weight loss has completed enrollment of adults living with obesity or overweight with elevated liver fat.

Repatha

  • In August, results from a new pre-specified analysis of the Phase 3 VESALIUS-CV pre-cardiovascular event trial on the protective effects of Repatha on fatal outcomes were presented at the European Society of Cardiology (ESC) Congress.

  • In this study, Repatha was associated with a nominal:

  • 20% reduction in all-cause mortality

  • 21% reduction in cardiovascular death

  • 15% reduction in non-cardiovascular death, largely explained by lower rates of non-fatal myocardial infarction, stroke, and ischemia-driven revascularization

  • Repatha also demonstrated that the reduction in mortality began around 1.5 years after treatment and continued through a median 4.6 years of follow-up.

  • In August, results from a new pre-specified analysis of the Phase 3 VESALIUS-CV trial on the protective effect of Repatha on total cardiovascular events were also presented at ESC Congress. In this study, Repatha:

  • reduced the total number of MACE (major adverse cardiac events), providing support for the role of intensive low-density lipoprotein cholesterol lowering to prevent first and subsequent MACE in patients at high cardiovascular risk and no prior MI or stroke

  • demonstrated a 27% relative reduction in the risk of a composite of coronary heart disease death, heart attack or ischemic stroke (3-P MACE)

  • demonstrated a 20% reduction in a broader composite that also included ischemia-driven revascularization (4-P MACE)

  • EVOLVE-MI, a Phase 4 study of Repatha initiated within 10 days of an acute myocardial infarction to reduce the risk of cardiovascular events, is ongoing.

Olpasiran (AMG 890)

  • Olpasiran is a potentially best-in-class small interfering ribonucleic acid (siRNA) molecule that reduces lipoprotein(a) (Lp(a)) synthesis in the liver.

  • The OCEAN(a)-Outcomes trial, a Phase 3 secondary prevention CV outcomes study, is ongoing in patients with established atherosclerotic CV disease and elevated Lp(a).

  • The OCEAN(a)-PreEvent trial, a Phase 3 primary prevention CV outcomes study, is enrolling patients with elevated Lp(a) at high risk for a first major CV event.

  • The OCEAN(a)-Coronary Computed Tomography Angiography (CCTA), a Phase 3 coronary artery plaque study, is enrolling patients with atherosclerotic CV disease and elevated Lp(a).

Rare Disease

UPLIZNA

  • MERCURY, a Phase 2/3 study of UPLIZNA, was initiated in patients with autoimmune hepatitis (AIH).

  • MOMENT, a Phase 3 study of UPLIZNA, was initiated in patients with primary membranous nephropathy (PMN).

  • In September, new one-year extension data from the Phase 3 MINT study in patients with generalized myasthenia gravis (gMG) were presented at Annual Neuromuscular Study Group (NMSG) and at the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting. Key findings included:

  • sustained numerical improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores at Year 1 of the open label period (OLP)

  • observed improvements both in participants who continued UPLIZNA from the randomized controlled period (RCP) and in those who initiated UPLIZNA during the OLP, demonstrating similar patterns of improvement regardless of initial treatment assignment

  • UPLIZNA continued to demonstrate a safety profile consistent with the established safety profile of UPLIZNA across all approved indications

  • efficacy and safety outcomes support the longer-term use of UPLIZNA for the treatment of gMG

  • A Phase 3 study of UPLIZNA in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) will be initiated H2 2026 - H1 2027.

TEPEZZA

  • Chronic-J, a Phase 3 study of TEPEZZA in Japanese patients with chronic thyroid eye disease (TED) met both primary endpoints, with a safety profile consistent with the established profile. The results will be shared with the scientific community and regulatory authorities.

TAVNEOS

  • The Company continues to engage the U.S. Food and Drug Administration (FDA) regarding the Center for Drug Evaluation and Research's request to voluntarily withdraw TAVNEOS from the U.S. market. On June 1, 2026, the Company requested a hearing to discuss this topic and submitted supporting materials to the FDA on July 23, 2026. The Company believes that these materials support a favorable benefit-risk profile of TAVNEOS for patients with AAV.

  • A Phase 3, open-label study of TAVNEOS in combination with rituximab or a cyclophosphamide-containing regimen is ongoing in patients from six years to < 18 years of age with active AAV (Granulomatosis with Polyangiitis (GPA)/Microscopic Polyangiitis (MPA)).

Dazodalibep

  • Dazodalibep is a fusion protein that inhibits CD40 ligand (CD40L).

  • In October, the Company announced results from the Phase 3 OASIZ-301 study of dazodalibep in adults with Sjögren's disease and moderate-to-severe systemic disease activity with full results to be presented as a late-breaking oral presentation at the American College of Rheumatology (ACR) Convergence in November. In this study, dazodalibep:

  • achieved statistically significant and clinically meaningful improvements of systemic disease activity at Week 48 with a change from baseline of 5.6 points with every-four-week dosing (1.8 points placebo-adjusted improvement) and 5.2 points with every-12-week dosing (1.4 points placebo-adjusted improvement), as measured by the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)

  • observed evidence of clinical benefit as early as Week 4

  • demonstrated statistically significant and clinically meaningful improvements of patient-reported dryness, a key secondary endpoint, at Week 48 with a change from baseline of 2.50 points (1.17 points placebo-adjusted improvement) and 1.98 points (0.93 points placebo-adjusted improvement) with every-four-week dosing, as measured by the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) dryness score and the Diary for Assessing Sjögren's Patient Reported Index (DASPRI) dryness score, respectively

  • demonstrated a favorable safety profile that was similar across treatment groups

  • OASIZ 303, the Phase 3 study of dazodalibep in Sjögren's patients with moderate-to-severe symptom burden with low systemic disease activity, is ongoing and is expected to complete in Q4 2026.

AMG 732

  • AMG 732 is an insulin-like growth factor-1 receptor (IGF-1R) targeting monoclonal antibody.

  • A Phase 2 study of AMG 732 is ongoing in patients with moderate-to-severe active TED.

Inflammation

Otezla

  • A Phase 3 study evaluating the safety of Otezla in pediatric patients aged six through 17 years with mild-to-moderate plaque psoriasis has been completed. The safety findings were consistent with the established safety profile of Otezla. The Company plans to submit the results to the FDA.

TEZSPIRE

  • In October, the results from the Phase 3 CROSSING study of TEZSPIRE in eosinophilic esophagitis (EOE) were presented at the American College of Gastroenterology (ACG) and the United European Gastroenterology Week (UEGW). In this study, TEZSPIRE dosed every four weeks:

  • achieved histologic remission at Week 24 in 64.8% and 68.9% of EoE patients receiving the 210 mg and 420 mg doses, respectively, vs 3.5% for placebo

  • reduced the frequency and severity of dysphagia symptoms at Week 24 by 18.8 points and 22.0 points in EoE patients receiving 210 mg and 420 mg doses, respectively, vs 14.7 points for placebo, as measured by the Dysphagia Symptom Questionnaire (DSQ) score

  • sustained histological remission and continued symptom improvement through Week 52

  • achieved total endoscopic remission at Week 52 in 34.4% and 29.5% of EoE patients receiving the 210 mg and 420 mg doses, respectively, vs 4.1% for placebo

  • demonstrated a safety profile consistent with its approved indications

  • Two Phase 3 studies of TEZSPIRE are enrolling adults with moderate to very severe chronic obstructive pulmonary disease (COPD) and a blood eosinophil count (BEC) ≥ 150 cells/µL.

Daxdilimab

  • Daxdilimab is a first-in-class plasmacytoid dendritic cell depleting monoclonal antibody targeting immunoglobulin-like transcript 7 (ILT7).

  • In September, results from the Phase 2 study of daxdilimab in adult patients with moderate-to-severe primary discoid lupus erythematosus (DLE) were presented at the European Academy of Dermatology and Venereology (EADV). In this study, daxdilimab dosed every four weeks:

  • achieved statistically significant and clinically meaningful improvements in disease activity by 10.2 points with low dose (6.0 points placebo-adjusted improvement) and 9.9 points with high dose (5.7 points placebo-adjusted improvement), as measured by the change from baseline of the Cutaneous Lupus Erythematosus Disease Area and Severity Index - Activity (CLASI-A) score at Week 24

  • showed statistically significant improvement in disease activity as early as Week 4 with the low dose and Week 8 with the high dose

  • demonstrated a ≥50% reduction in CLASI-A score (CLASI-50) at Week 24 in 61.7% of patients on low dose (38.0% placebo-adjusted improvement) and 62.1% of DLE patients on high dose (38.4% placebo-adjusted improvement)

  • achieved a clear or almost-clear skin at Week 24 in 60.3% of patients on low dose (51.5% placebo-adjusted improvement) and 51.6% of DLE patients on high dose (42.8% placebo-adjusted improvement), as measured by the proportion of patients achieving the Cutaneous Lupus Activity Investigator's Global Assessment (CLA-IGA 0/1)

  • demonstrated a favorable safety profile, with no serious adverse events or deaths reported

  • The Company is taking steps to advance daxdilimab to Phase 3 development.

Blinatumomab

  • Blinatumomab is a bispecific T-cell engager (BiTE®) molecule targeting CD19.

  • A Phase 2 study of blinatumomab in autoimmune disease is enrolling adults with refractory rheumatoid arthritis.

  • A Phase 2 study of blinatumomab in autoimmune disease is ongoing in adults with systemic lupus erythematosus (SLE), with and without nephritis.

Inebilizumab

  • Inebilizumab is a B-cell depleting monoclonal antibody targeting CD19.

  • A Phase 2 study of inebilizumab in autoimmune disease has completed enrollment of adults with SLE with nephritis.

Sunakiment (AMG 104/AZD8630)

  • Sunakiment is an inhaled anti-thymic stromal lymphopoietin (TSLP) fragment antigen-binding (Fab) protein.

  • The Company is planning a Phase 3 development program in asthma in collaboration with AstraZeneca.

Oncology

BLINCYTO/blinatumomab

  • Golden Gate, a Phase 3 study of BLINCYTO alternating with low-intensity chemotherapy, is ongoing in older adult patients with newly diagnosed CD19-positive Philadelphia chromosome (Ph) negative B-cell precursor acute lymphoblastic leukemia (B-ALL).

  • A potentially registration-enabling Phase 2 study of subcutaneous blinatumomab in both adults and adolescents with relapsed or refractory CD19-positive Ph-negative B-ALL remains on partial clinical hold by the FDA.

  • A Phase 1b/2 study of subcutaneous blinatumomab in pediatric patients with relapsed or refractory and minimal residual disease positive (MRD+) B-ALL remains on partial clinical hold by the FDA.

  • Discussions are underway with the FDA on a path forward to reopen both subcutaneous blinatumomab studies.

IMDELLTRA/tarlatamab

  • IMDELLTRA is the first and only FDA-approved delta-like ligand 3 (DLL3) targeting BiTE molecule.

  • In September, the FDA approved an update to the IMDELLTRA Prescribing Information, reducing the recommended monitoring time for the first two doses from 22 to 24 hours to 6 to 8 hours from the start of infusion in an appropriate healthcare setting.

  • In September, at the World Conference on Lung Cancer (WCLC), two key IMDELLTRA results were presented:

  • A Phase 2 alternate dosing study, DeLLphi-309, evaluating IMDELLTRA dosed every three weeks or every four weeks, demonstrated durable objective response and maintained overall survival (OS) in both dosing frequencies compared to the established every 2 week dosing. Extended dosing regimens may offer flexibility in treatment combination for small cell lung cancer (SCLC) patients who are often taking other therapies

  • Results from the Phase 1b DeLLphi-308 subcutaneous administration study showed for the first time that subcutaneous IMDELLTRA can achieve comparable exposures to the intravenous route, to be further characterized in the Phase 3 DeLLphi-315 study

  • In October, three key IMDELLTRA results were presented at the European Society for Medical Oncology (ESMO) Congress:

  • The landmark Phase 3 DeLLphi-305 study showed that addition of IMDELLTRA to IMFINZI**®** (durvalumab) in first-line maintenance therapy significantly improved OS (58% reduction in risk of death) and progression-free survival (66% reduction in risk of disease progression or death) for patients who completed initial chemo-immunotherapy without progression. The DeLLphi-305 results were published simultaneously in the New England Journal of Medicine

  • IMDELLTRA continued to demonstrate a safety profile consistent with the established safety profile of IMDELLTRA in the approved second-line setting

  • A long-term update with a median follow-up of 30.8 months from the Phase 1b DeLLphi-303 first-line maintenance study, showed an estimated median OS of 37.9 months among patients that received IMDELLTRA plus a PD-L1 inhibitor as a first-line maintenance regimen following initial chemo-immunotherapy

  • A long-term update from the Phase 3 DeLLphi-304 study, which established IMDELLTRA as the standard of care for patients who have had progression on or after platinum-based chemotherapy, showed sustained OS benefit with twice as many patients alive at two years with IMDELLTRA (30%) compared to standard chemotherapy (15%). The DeLLphi-304 results were published simultaneously in Annals of Oncology

  • The Company is advancing a comprehensive, global clinical development program across extensive-stage (ES) and limited-stage (LS) SCLC:

  • DeLLphi-303, a Phase 1b study of IMDELLTRA in combination with a programmed cell death protein ligand-1 (PD-L1) inhibitor, carboplatin and etoposide or separately in combination with a PD-L1 inhibitor alone, is ongoing in patients with first-line ES-SCLC

  • DeLLphi-306, a Phase 3 study of IMDELLTRA following concurrent chemoradiation therapy, is ongoing in patients with LS-SCLC

  • DeLLphi-308, a Phase 1b study evaluating subcutaneous tarlatamab, is enrolling patients with second-line or later ES-SCLC

  • DeLLphi-310, a Phase 1b study of IMDELLTRA in combination with YL201, a B7-H3 targeting antibody-drug conjugate (ADC), with or without a PD-L1 inhibitor, is ongoing in patients with ES-SCLC

  • DeLLphi-311, a Phase 1b study of IMDELLTRA in combination with etakafusp alfa (AB248), a novel CD8+ T-cell selective interleukin-2 (IL-2), is ongoing in patients with second-line or later ES-SCLC

  • DeLLphi-312, a Phase 3 study of IMDELLTRA in combination with carboplatin, etoposide and durvalumab, has completed enrollment of patients with first-line ES-SCLC

  • DeLLphi-313, a Phase 1b study of IMDELLTRA in combination with zocilurtatug pelitecan, a DLL3 targeting ADC, with and without a PD-L1 inhibitor, is enrolling patients with ES-SCLC

  • DeLLphi-315, a Phase 3 study of subcutaneous tarlatamab, is enrolling patients with second-line ES-SCLC

Xaluritamig (AMG 509)

  • Xaluritamig is a first-in-class BiTE molecule targeting six-transmembrane epithelial antigen of the prostate 1 (STEAP1).

  • XALute, a Phase 3 study of xaluritamig, is ongoing in patients with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with taxane-based chemotherapy.

  • XALience, a Phase 3 study of xaluritamig in combination with abiraterone, is enrolling patients with chemotherapy-naïve mCRPC.

  • A Phase 1 study of xaluritamig monotherapy and xaluritamig in combination with abiraterone is enrolling patients with mCRPC who have not yet received taxane-based chemotherapy. Results from a fully outpatient cohort of patients with mCRPC who have previously received taxane-based chemotherapy were presented at ESMO, demonstrating feasibility for a more convenient administration setting.

  • A Phase 1b study of neoadjuvant xaluritamig therapy prior to radical prostatectomy is enrolling patients with newly diagnosed localized intermediate or high–risk prostate cancer.

  • A Phase 1b study of xaluritamig is ongoing in patients with high-risk biochemically recurrent prostate cancer after definitive therapy.

  • A Phase 1b study of xaluritamig in combination with androgen receptor pathway inhibitors is enrolling patients with metastatic hormone-sensitive prostate cancer.

  • A Phase 1b study of xaluritamig is enrolling adults with mCRPC to evaluate an additional dosing regimen.

  • A Phase 1b study of xaluritamig is enrolling adult, adolescent and pediatric patients with relapsed or refractory Ewing sarcoma.

LUMAKRAS/LUMYKRAS

  • CodeBreaK 301, a Phase 3 study of LUMAKRAS in combination with Vectibix and FOLFIRI vs. FOLFIRI with or without bevacizumab-awwb, is enrolling patients with first-line KRAS G12C–mutated metastatic colorectal cancer.

  • CodeBreaK 202, a Phase 3 study of LUMAKRAS plus platinum doublet chemotherapy vs. pembrolizumab plus chemotherapy, is enrolling patients with first-line KRAS G12C–mutated and PD-L1 negative advanced non-small cell lung cancer (NSCLC).

Nplate

  • PROCLAIM, a Phase 3 study of Nplate for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients with NSCLC, ovarian cancer, or breast cancer is complete. Full results will be presented at an upcoming medical congress.

  • ROMISTER, a Phase 3 study of Nplate plus predniso(lo)ne compared with predniso(lo)ne alone, is enrolling patients with untreated primary immune thrombocytopenia (ITP).

Biosimilars

  • A randomized, double-blind comparative clinical study of ABP 206 compared with OPDIVO® (nivolumab) is ongoing in patients with treatment-naïve unresectable or metastatic melanoma. The Biologics License Application (BLA) with the FDA has been submitted and accepted for review. The Company expects an FDA action on this BLA by the end of the year.

  • A randomized, double-blind combined pharmacokinetic/comparative clinical study of ABP 234 compared with KEYTRUDA® (pembrolizumab) in patients with advanced or metastatic non-squamous NSCLC has met both primary and secondary endpoints. We have submitted these results and are awaiting file acceptance by the FDA.

  • A randomized, double-blind pharmacokinetic similarity study of ABP 234 compared with KEYTRUDA® in patients with early-stage non-squamous NSCLC as adjuvant treatment has met both primary and secondary endpoints.

  • A randomized, double-blind, pharmacokinetic similarity/comparative clinical study of ABP 692 compared with OCREVUS® (ocrelizumab) is ongoing in patients with relapsing-remitting multiple sclerosis.

  • A randomized, double-blind, comparative clinical study of ABP 938 (8 mg) compared with EYLEA HD® (aflibercept) is enrolling patients with neovascular age-related macular degeneration.

TEZSPIRE is being developed in collaboration with AstraZeneca.

Sunakiment (AMG 104/AZD8630) is being developed in collaboration with AstraZeneca.

Xaluritamig, formerly AMG 509, is being developed pursuant to a research collaboration with Xencor, Inc.

YL201 is an investigational B7-H3 targeting antibody-drug conjugate being developed by MediLink.

Zocilurtatug pelitecan is an investigational DLL3 targeting antibody-drug conjugate being developed by Zai Lab Limited.

Etakafusp alfa (AB248) is a novel CD8+ T cell selective IL-2 being developed by Asher Biotherapeutics.

OPDIVO is a registered trademark of Bristol-Myers Squibb Company.

KEYTRUDA is a registered trademark of Merck & Co., Inc.

OCREVUS is a registered trademark of Genentech, Inc.

EYLEA HD is a registered trademark of Regeneron Pharmaceuticals, Inc.

IMFINZI is a registered trademark of AstraZeneca PLC.

Non-GAAP Financial Measures

In this news release, management has presented its operating results for the third quarters of 2026 and 2025, in accordance with U.S. Generally Accepted Accounting Principles (GAAP) and on a non-GAAP basis. In addition, management has presented its full year 2026 EPS and tax guidance in accordance with GAAP and on a non-GAAP basis. These non-GAAP financial measures are computed by excluding certain items related to acquisitions, restructuring and certain other items from the related GAAP financial measures. Management has presented Free Cash Flow (FCF), which is a non-GAAP financial measure, for the third quarters of 2026 and 2025. FCF is computed by subtracting capital expenditures from operating cash flow, each as determined in accordance with GAAP.

The Company believes that its presentation of non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors. The Company uses certain non-GAAP financial measures to enhance an investor's overall understanding of the financial performance and prospects for the future of the Company's normal and recurring business activities by facilitating comparisons of results of normal and recurring business operations among current, past and future periods. The Company believes that FCF provides a further measure of the Company's liquidity.

The Company uses the non-GAAP financial measures set forth in the news release in connection with its own budgeting and financial planning internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets. The non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines.

More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, heart disease, inflammatory conditions, rare diseases and obesity and obesity-related conditions.

Amgen has been consistently recognized for innovation and workplace culture, including honors from Fast Company and Forbes. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.

Prompts

Amgen Inc. (ticker AMGN), listed in United States.

Company History

Date Change Detail
Aug 8, 2023 Acquired Acquired Horizon Therapeutics Public Ltd Co (CIK 1492426). Its filings from before the deal are on its own company page, not shown here.
Aug 9, 2013 Acquired Acquired Onyx Pharmaceuticals Inc (CIK 1012140). Its filings from before the deal are on its own company page, not shown here.
Mar 2, 2012 Acquired Acquired Micromet, Inc. (CIK 1131907). Its filings from before the deal are on its own company page, not shown here.

ETFs Holding Amgen Inc.

ETF Weight in ETF Shares Market value As of
ROPE 6.08% 3,280 $ 1.5M Nov 18, 2026
EGGS 5.74% 5,957 $ 2.754M Nov 17, 2026
DOGG 5.05% 10,489 $ 4.91M Nov 11, 2026
YALL 4.70% 7,494 $ 3.465M Nov 17, 2026
DIVO 4.19% 831,999 $ 301.283M Jun 30, 2026
ELCV 4.18% 27,230 $ 10.488M Jul 31, 2026
DDDD 4.06% 684 $ 316.227K Nov 17, 2026
MEDX 3.91% 2,062 $ 746.691K Jun 30, 2026
FDV 3.77% 86,166 $ 33.188M Jul 31, 2026
DVGR 3.34% 1,221 $ 560K Nov 18, 2026
CCOR 3.15% 2,281 $ 878.55K Jul 31, 2026
OZEM 3.02% 3,689 $ 1.689M Nov 17, 2026
DIVN 2.87% 20,495 $ 8.81M Aug 31, 2026
TBG 2.78% 20,257 $ 9.28M Nov 18, 2026
MBOX 2.76% 9,288 $ 4.25M Nov 18, 2026
PINK 2.74% 20,014 $ 9.165M Nov 17, 2026
BMED 2.59% 802 $ 370.781K Nov 16, 2026
BAMD 2.52% 5,783 $ 2.486M Aug 31, 2026
DIVL 2.51% 4,164 $ 1.508M Jun 30, 2026
ESLV 2.44% 905 $ 348.57K Jul 31, 2026
WCAP 2.20% 3,490 $ 1.344M Jul 31, 2026
FDIV 2.19% 3,339 $ 1.286M Jul 31, 2026
CANC 2.06% 10,097 $ 4.34M Aug 31, 2026
GDIV 1.80% 9,557 $ 4.45M Nov 13, 2026
DUHP 1.74% 725,432 $ 338.82M Nov 12, 2026
FTHI 1.73% 94,446 $ 43.664M Nov 16, 2026
ZECP 1.48% 12,963 $ 5.573M Aug 31, 2026
HRTS 1.47% 1,901 $ 817.202K Aug 31, 2026
AVIE 1.40% 503 $ 232.547K Nov 16, 2026
BRIF 1.38% 5,894 $ 2.134M Jun 30, 2026
SIXA 1.34% 16,290 $ 7.608M Nov 12, 2026
VUS 1.29% 600 $ 231.096K Jul 31, 2026
CLCV 1.27% 563 $ 216.845K Jul 31, 2026
CGDV 1.19% 986,677 $ 456.161M Nov 16, 2026
MODL 1.17% 33,158 $ 12.007M Jun 30, 2026
FTQI 1.12% 23,260 $ 10.754M Nov 16, 2026
PAYR 1.08% 1,607 $ 618.952K Jul 31, 2026
FLCV 1.08% 3,506 $ 1.507M Aug 31, 2026
QDVO 1.07% 21,916 $ 7.936M Jun 30, 2026
ESUM 1.06% 5,032 $ 1.938M Jul 31, 2026
ABFL 1.05% 14,316 $ 5.514M Jul 31, 2026
BAMG 1.01% 2,998 $ 1.289M Aug 31, 2026
GQQQ 0.99% 3,565 $ 1.63M Nov 18, 2026
DFVX 0.98% 12,055 $ 5.63M Nov 12, 2026
FLCC 0.93% 2,888 $ 1.241M Aug 31, 2026
CGGR 0.92% 502,412 $ 232.275M Nov 16, 2026
CAPE 0.89% 5,876 $ 2.128M Jun 30, 2026
TUGN 0.86% 1,908 $ 690.925K Jun 30, 2026
LSEQ 0.80% 303 $ 141.098K Nov 13, 2026
VFMF 0.79% 17,866 $ 7.68M Aug 31, 2026
TFPN 0.75% 2,499 $ 1.155M Nov 17, 2026
OEI 0.74% 895 $ 344.718K Jul 31, 2026
TUG 0.74% 697 $ 252.398K Jun 30, 2026
LEXI 0.69% 3,054 $ 1.313M Aug 31, 2026
CGBL 0.68% 116,969 $ 54.077M Nov 16, 2026
WBIL 0.68% 568 $ 205.684K Jun 30, 2026
CGCV 0.63% 33,341 $ 15.414M Nov 16, 2026
LCTU 0.63% 15,275 $ 7.062M Nov 16, 2026
TIME 0.63% 200 $ 92.464K Nov 17, 2026
PHEQ 0.59% 2,287 $ 828.168K Jun 30, 2026
BIGY 0.59% 360 $ 166.435K Nov 17, 2026
XMAG 0.58% 2,688 $ 1.255M Nov 13, 2026
BALI 0.58% 19,126 $ 8.842M Nov 16, 2026
VSLU 0.58% 8,725 $ 3.159M Jun 30, 2026
DFSU 0.58% 29,465 $ 13.762M Nov 12, 2026
LSVD 0.55% 9,260 $ 3.567M Jul 31, 2026
TACU 0.54% 214 $ 98.936K Nov 17, 2026
GINX 0.54% 1,334 $ 573.46K Aug 31, 2026
INRO 0.52% 6,623 $ 3.062M Nov 16, 2026
MPLY 0.51% 209 $ 80.498K Jul 31, 2026
ESLG 0.51% 305 $ 117.474K Jul 31, 2026
TGRT 0.49% 16,933 $ 7.828M Nov 17, 2026
JEPQ 0.48% 428,503 $ 196.224M Nov 17, 2026
BTAL 0.45% 3,542 $ 1.283M Jun 30, 2026
LDRX 0.45% 2,676 $ 1.15M Aug 31, 2026
FTLS 0.45% 25,107 $ 0.00 Nov 16, 2026
CGDG 0.44% 56,659 $ 26.195M Nov 16, 2026
JGRO 0.44% 87,204 $ 39.933M Nov 17, 2026
AVUQ 0.43% 3,954 $ 1.828M Nov 16, 2026
PEPS 0.42% 338 $ 122.397K Jun 30, 2026
DCOR 0.42% 402,378 $ 187.935M Nov 12, 2026
ACIO 0.41% 25,134 $ 9.681M Jul 31, 2026
ADME 0.40% 3,043 $ 1.172M Jul 31, 2026
DFAC 0.38% 720,563 $ 336.546M Nov 12, 2026
MSLC 0.38% 36,262 $ 15.588M Aug 31, 2026
TVAL 0.38% 9,385 $ 4.339M Nov 17, 2026
CLSE 0.38% 7,886 $ 3.39M Aug 31, 2026
DFAU 0.37% 102,549 $ 47.897M Nov 12, 2026
DFUS 0.37% 169,552 $ 79.191M Nov 12, 2026
AVSU 0.36% 3,782 $ 1.748M Nov 16, 2026
HUSV 0.36% 444 $ 205.27K Nov 16, 2026
SCLZ 0.36% 194 $ 70.251K Jun 30, 2026
ENHU 0.34% 68 $ 31.438K Nov 16, 2026
DXUV 0.33% 44,704 $ 20.879M Nov 12, 2026
MKTN 0.33% 986 $ 357.05K Jun 30, 2026
APUE 0.33% 19,321 $ 8.306M Aug 31, 2026
IQSZ 0.33% 1,481 $ 570.422K Jul 31, 2026
GEW 0.32% 1,069 $ 459.542K Aug 31, 2026
NANC 0.32% 1,854 $ 857.141K Nov 17, 2026
VOXP 0.30% 45 $ 17.332K Jul 31, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
AMGN canonical Common share — US nasdaq 421.51 USD 2026-09-30
4332 Common share — HK hkex — —